Overview

Capecitabine Metronomic Chemotherapy Plus Aromatase Inhibitor for Postmenopausal Hormone Receptor Positive Breast Cancer

Status:
Unknown status

Trial end date:
2015-06-01

Target enrollment:

Participant gender:

Summary

The present study is to determine the adverse effects and clinical efficacy of AI combined with Capecitabine metronomic chemotherapy in postmenopausal breast cancer patients with Estrogen receptor and/or Progestrogen receptor positive.

Phase:

Phase 2

Details

Lead Sponsor:

Fudan University

Treatments:

Aromatase Inhibitors
Capecitabine
Hormones